COLL News and Press, Collegium Pharmaceutical Inc. From 02/23/23

Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Conference Call February 23, 2023, 04:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chie...

Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q4 Non-GAAP EPS of $1.09 misses by $0.17 . Revenue of $129.62M (+373.8% Y/Y) beats by $4.41M . For further details see: Collegium Pharmaceutical Non-GAAP EPS of $1.09 misses by $0.17, revenue of $129.62M be...

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 ...

STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report. The report reflects the Company’s ...

Collegium Pharmaceutical ( NASDAQ: COLL ) prices $ 210M aggregate principal amount of 2.875% convertible senior notes due 2029 in a private offering. The offering was upsized from the previously announced offering size of $175M aggregate principal amount of notes. Initial ...

STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified insti...

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private o...

-Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a le...

Summary Small caps outperformed the Nasdaq Composite last year as stocks fell due to the Federal Reserve's efforts to control inflation. Market fears are mounting that the economy may slip into a recession, but there are opportunities in small-cap stocks. The potential risk of a lon...

Summary Collegium Pharmaceutical has caught a strong bid since bouncing off 52-week lows last October. A number of catalysts have driven the stock up the page and shares now trade at multi-year highs. The company projects strong growth prospects in FY23. Delving deeper into the ...